日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial

Duvelisib联合罗米地辛治疗复发/难治性T细胞淋巴瘤:一项1b/2a期试验

Steven M Horwitz ,Ajit J Nirmal ,Jahan Rahman # ,Ran Xu # ,Esther Drill ,Natasha Galasso ,Nivetha Ganesan ,Theresa Davey ,Helen Hancock ,Leslie Perez ,Catherine Maccaro ,Alexandra Bahgat ,Evan Marzouk ,Elizabeth Cathcart ,Alison Moskowitz ,Ariela Noy ,Anita Kumar ,Eric Jacobsen ,David C Fisher ,Neha Mehta-Shah ,Youn H Kim ,Michael Khodadoust ,Nikita Kotlov ,Anastasia Nikitina ,Olga Kudryashova ,Valeria Zubareva ,Ksenia Zornikova ,Nara Shin ,Maria Sorokina ,Sandrine Degryse ,Ekaterina Postovalova ,Aleksander Bagaev ,Kinga Hosszu ,Devin McAvoy ,Jaap J Boelens ,Wenchao Wu ,Zoe Ciantra ,Jackson W Appelt ,Christopher Trevisani ,Sam Amaka ,David M Weinstock ,Santosha A Vardhana

ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas

ITK 降解可阻断 T 细胞受体信号传导并克服 T 细胞淋巴瘤的治疗耐药性

Baishan Jiang, David M Weinstock, Katherine A Donovan, Hong-Wei Sun, Ashley Wolfe, Sam Amaka, Nicholas L Donaldson, Gongwei Wu, Yuan Jiang, Ryan A Wilcox, Eric S Fischer, Nathanael S Gray, Wenchao Wu

Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1

通过有效降解 ZFP91 和 IKZF1 克服 T 细胞淋巴瘤中的 IMiD 耐药性

Wenchao Wu, Geoffrey M Nelson, Raphael Koch, Katherine A Donovan, Radosław P Nowak, Tayla B Heavican-Foral, Ajit J Nirmal, Huiyun Liu, Lei Yang, Jessica Duffy, Foster Powers, Kristen E Stevenson, Marcus Kenneth Jones, Samuel Y Ng, Gongwei Wu, Salvia Jain, Ran Xu, Sam Amaka, Christopher Trevisani, Ni